IBM's Earnings Are Coming. Watch for More Details on Its Spinoff. 

When the tech company reports earnings on Monday, investors are likely to focus on any new details about IBM's planned spinoff of its managed information services business.

GM to Help Build $2.3 Billion Battery Plant in Tennessee 

Factory will be the second for the auto maker's joint venture with LG Chem, one of the largest makers of batteries for electric vehicles.

Morgan Stanley Books Archegos Loss, but Profit Hits a High 

The bank lost $911 million when Archegos Capital Management imploded last month, tarnishing a record-setting quarter.

Indianapolis Mass Shooting: At Least Eight Dead at FedEx Facility 

The gunman arrived at the parking lot, got out of his car and started shooting. After killing people outside and inside the facility, he apparently killed himself.

Apple Music Reveals How Much It Pays When You Stream a Song 

The company pays the music industry a penny per stream on its service, a disclosure it made as part of an effort by music-streaming services to show they are artist-friendly.

Hertz Bankruptcy Bidding War Heats Up With New Counteroffer 

Knighthead Capital Management and Certares Management, which previously offered to buy Hertz out of bankruptcy but were eclipsed by a competing group, returned with a sweetened bid.

Simon & Schuster Won't Distribute Policeman's Book About Breonna Taylor Shooting 

The book's author, Jonathan Mattingly, was one of the three Louisville police officers who fired their weapons during last year's raid.

ESG Insights - Johnson & Johnson Under the Microscope 

This week, The Wall Street Journal's ESG research analysts looked at J&J's vaccine pause, Microsoft's acquisition of Nuance, the Veolia-Suez deal, Air Canada and more.

Toshiba Shareholders May Finally Get Their Due 

Storied Japanese company Toshiba has a long history of governance problems, but the prospect of a bidding war means things could finally be looking up.

J&J Privately Asked Rival Vaccine Makers to Probe Clot Risks 

AstraZeneca was interested in joining forces to investigate the safety issue and communicate vaccine benefits and risks, but Pfizer and Moderna didn't see the need for group action.


(END) Dow Jones Newswires

April 16, 2021 15:00 ET (19:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.